Re­mem­ber that mega-block­buster val­u­a­tion Ab­b­Vie as­signed to Ro­va-T? It’s start­ing to van­ish — qui­et­ly

Ab­b­Vie ex­ecs have fi­nal­ly got­ten around to do­ing what a host of an­a­lysts man­aged to ac­com­plish long ago: writ­ing down the val­ue of their once much-vaunt­ed can­cer drug Ro­va-T.

Way down.

On Fri­day the com­pa­ny filed a no­tice with the SEC ex­plain­ing that Ab­b­Vie $AB­BV has de­cid­ed to knock $4 bil­lion off the book val­ue of the drug weeks af­ter re­searchers were forced to stop re­cruit­ing pa­tients in the now in­fa­mous TAHOE study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER